Loading
A phase 2 trial of VS-7375 in non-small-cell lung cancer and small-cell lung cancer, run by Verastem, Inc., now recruiting.
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07659782 by Verastem, Inc., with 105 participants planned, started 2026-07-22 and due to reach its primary completion in 2027-06. Interventions recorded: VS-7375. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares VS-7375, Verastem Oncology, Small-cell lung cancer, Non-small-cell lung cancer.
Shares VS-7375, Verastem Oncology.
Shares VS-7375, Verastem Oncology.
Shares Verastem Oncology, Small-cell lung cancer, Non-small-cell lung cancer.